Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study

BACKGROUND: Vemurafenib, a novel selective small molecule inhibitor of BRAF, has recently been shown to be effective in the treatment of melanomas harboring the BRAF V600E mutation. Similar to the broad-spectrum RAF inhibitor sorafenib, vemurafenib induces development of squamous cell carcinomas and...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Am Acad Dermatol
Main Authors: Chu, Emily Y., Wanat, Karolyn A., Miller, Christopher J., Amaravadi, Ravi K., Fecher, Leslie A., Brose, Marcia S., McGettigan, Suzanne, Giles, Lydia R., Schuchter, Lynn M., Seykora, John T., Rosenbach, Misha
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4838029/
https://ncbi.nlm.nih.gov/pubmed/22609219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaad.2012.04.008
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares